Drugs for Avian Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 51)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Oseltamivir |
Approved |
Phase 4 |
|
204255-11-8, 196618-13-0 |
65028 |
Synonyms:
(-)-oseltamivir
(−)-oseltamivir
(-)-Oseltamivir
(3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acid
(3R,4R,5S)-4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid
196618-13-0
204255-11-8
4-Acetylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-enecarboxylic acid
AC1L22FK
AC1Q63H0
Agucort
Agucort (TN)
BIDD:GT0426
BRD-K76011241-045-01-5
C08092
CHEBI:7798
CHEMBL1229
CID65028
D08306
DB00198
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate
ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate
Ethyl (5S,3R,4R)-4-(acetylamino)-5-amino-3-(ethylpropoxy)cyclohex-1-enecarboxylate
|
FT-0082384
GS 4104
GS4104
GS-4104
HMS2090C11
HSDB 7433
LS-57422
MolPort-005-933-026
NCGC00178698-01
oseltamivir
Oseltamivir
Oséltamivir
Oseltamivir (INN)
Oseltamivir [INN:BAN]
Oseltamivir phosphate
oseltamivirum
Oseltamivirum
Ro-640796
Ro-64-0796
Tamiflu
Tamiflu (*Phosphate salt 1:1*)
Tamiflu-Free
Tamvir
UNII-20O93L6F9H
|
|
2 |
|
Probenecid |
Approved, Investigational |
Phase 4 |
|
57-66-9 |
4911 |
Synonyms:
4-((dipropylamino)Sulfonyl)benzoate
4-((dipropylamino)Sulfonyl)benzoic acid
4-((Dipropylamino)sulfonyl)benzoic acid
4-((dipropylamino)Sulphonyl)benzoate
4-((dipropylamino)Sulphonyl)benzoic acid
4-(Di-n-propylsulfamoyl)benzoesaeure
4-(Di-N-propylsulfamoyl)benzoesaeure
4-(Di-n-propylsulfamoyl)benzoesäure
4-(Di-N-propylsulphamoyl)benzoesaeure
4-(Dipropylsulfamoyl)benzoic acid
4-(N,N-Dipropylsulfamoyl)benzoesaeure
4-(N,N-Dipropylsulfamoyl)benzoesäure
4-(N,N-Dipropylsulphamoyl)benzoesaeure
4-[(dipropylamino)sulfonyl]benzoic acid
57-66-9
AB00052080
AC1L1J86
AC1Q2XQM
AC1Q2XQN
AC-2023
AI3-50078
AKOS000165123
Apurina
Bencid
Benecid
Benemid
Benemid (TN)
Benemide
Benuryl
BIDD:GT0626
BIDD:PXR0092
Biokanol brand OF probenecid
Biokanol Brand of Probenecid
BPBio1_000643
BRD-K95237249-001-05-9
BRN 2815775
BSPBio_000583
BSPBio_002227
C07372
C13H19NO4S
CAS-57-66-9
CCRIS 3643
CHEBI:177474
CHEMBL897
CID4911
Colbenemid
Col-BENEMID
ColBenemid (co mponent of)
ColBenemid (component of)
Col-Probenecid
CPD000058280
D00475
D011339
DB01032
DivK1c_000056
EINECS 200-344-3
HMS1569N05
HMS1920J22
HMS2092C03
HMS500C18
HSDB 3387
I01-1905
ICN brand OF probenecid
ICN Brand of Probenecid
IDI1_000056
IDIS brand OF probenecid
IDIS Brand of Probenecid
KBio1_000056
KBio2_001314
KBio2_003882
KBio2_006450
KBio3_001727
KBioGR_000971
KBioSS_001314
LS-33
Major brand OF probenecid
Major Brand of Probenecid
Martec brand OF probenecid
Martec Brand of Probenecid
Merck brand OF probenecid
Merck Brand of Probenecid
MLS000028496
MLS001076472
MolPort-000-145-935
NCGC00016251-01
NCGC00016251-02
NCGC00023829-03
NCGC00023829-04
|
NCGC00023829-05
NCGC00023829-06
NCI-C56097
NINDS_000056
NSC 18786
NSC18786
Ophthalmic brand OF probenecid
Ophthalmic Brand of Probenecid
Oprea1_416955
P-(Dipropylsulfamoyl)benzoate
p-(Dipropylsulfamoyl)benzoic acid
P-(Dipropylsulfamoyl)benzoic acid
p-(Dipropylsulfamyl)benzoic acid
P-(Dipropylsulphamoyl)benzoate
P-(Dipropylsulphamoyl)benzoic acid
p-[Dipropylsulfamoyl]benzoic acid
P8761_SIGMA
Panuric
Parabenem
Parmed brand OF probenecid
Parmed Brand of Probenecid
Polycillin-BRB
Polycillin-PRB
Polycillin-PRB (component of)
Prestwick_809
Prestwick0_000542
Prestwick1_000542
Prestwick2_000542
Prestwick3_000542
Probalan
Probampacin
Probecid
Proben
Proben-C
probenecid
Probenecid
Probenecid (JP15/USP/INN)
Probenecid [INN:BAN:JAN]
Probenecid acid
Probenecid Acid
Probenecid major brand
Probenecid Major Brand
Probenecid martec brand
Probenecid Martec Brand
Probenecid parmed brand
Probenecid Parmed Brand
Probenecid weimer
Probenecid Weimer
Probenecid zenith brand
Probenecid Zenith Brand
Probenecida
Probenecida [INN-Spanish]
Probenecide
Probenecide [INN-French]
Probenecidum
Probenecidum [INN-Latin]
Probenemid
probenicid
Probenicid
Probenid
Probexin
pro-Cid
Pro-Cid
Prolongine
Robenecid
SAM002554923
SBB028597
SMR000058280
SPBio_001327
SPBio_002504
Spectrum_000834
SPECTRUM1500502
Spectrum2_001294
Spectrum3_000554
Spectrum4_000486
Spectrum5_001419
Sulprin
Synergid R
Tubophan
UNII-PO572Z7917
Uricosid
Urocid
Valdecasas brand OF probenecid
Valdecasas Brand of Probenecid
WLN: QVR DSWN3&3
Zenith brand OF probenecid
Zenith Brand of Probenecid
|
|
3 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
4 |
|
Lactitol |
Approved, Investigational |
Phase 3 |
|
585-88-6, 585-86-4 |
493591 |
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
Lactitol
Lactitolum
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
5 |
|
Formaldehyde |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
50-00-0 |
712 |
Synonyms:
Aldeide formica
Fannoform
Formaldehído
Formaldehyd
Formaldehyde
Formaldehyde solution
Formalin
FORMALIN
Formalina
Formaline
Formalith
|
Formic aldehyde
Formol
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
|
|
6 |
|
MF59 oil emulsion |
|
Phase 3 |
|
|
|
7 |
|
Hemagglutinins |
|
Phase 3 |
|
|
|
8 |
|
Agglutinins |
|
Phase 3 |
|
|
|
9 |
|
Laxatives |
|
Phase 3 |
|
|
|
10 |
|
Cathartics |
|
Phase 3 |
|
|
|
11 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
12 |
|
Anti-Inflammatory Agents |
|
Phase 3 |
|
|
|
13 |
|
Antimalarials |
|
Phase 3 |
|
|
|
14 |
|
Hydroxychloroquine |
Approved |
Phase 2 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
118-42-3
2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol
2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol
5-22-10-00280 (Beilstein Handbook Reference)
747-36-4 (sulfate (1:1) salt)
7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl)aminoquinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[4-(N-Ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
AC1L1GEW
Axemal
BRN 0253894
C07043
C18H26ClN3O
CHEMBL1535
CID3652
D08050
DB01611
DivK1c_000942
Dolquine
EINECS 204-249-8
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
|
Hidroxicloroquina
Hidroxicloroquina [inn-spanish]
Hidroxicloroquina [INN-Spanish]
HMS502P04
Hydroxychlorochin
Hydroxychloroguine
hydroxychloroquine
Hydroxychloroquine
Hydroxychloroquine (INN)
Hydroxychloroquine [INN:BAN]
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquine Sulfate (1:1) Salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Hydroxychloroquinum [INN-Latin]
IDI1_000942
Idrossiclorochina
Idrossiclorochina [dcit]
Idrossiclorochina [DCIT]
KBio1_000942
LS-66614
MolPort-003-847-792
NCGC00159483-02
NINDS_000942
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
PlaqueN/A
Plaquenil
Polirreumin
Polirreumin (TN)
Quensyl
SPBio_001116
Spectrum2_001238
Spectrum5_001697
ST072188
UNII-4QWG6N8QKH
WIN 1258
|
|
15 |
|
Azithromycin |
Approved |
Phase 2 |
|
83905-01-5 |
447043 55185 |
Synonyms:
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranoside
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside
121470-24-4
1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-,(2R-(2R*,3S*
75199_FLUKA
83905-01-5
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
AC-16014
AC1L9KEG
Aritromicina
Azadose
Azasite
Azenil
Azifast
Azigram
Azimakrol
Azithramycine
azithromycin
Azithromycin
Azithromycin & Tumor Necrosis Factor
Azithromycin (AIDS Initiative)
Azithromycin (anhydrous)
Azithromycin dihydrate
Azithromycin monohydrate
Azithromycin Monohydrate
Azithromycin pfizer brand
Azithromycine
Azithromycinum
Azitrocin
Azitromax
Azitromicina
Azitromin
Azythromycin
Bayer brand OF azithromycin dihydrate
BIDD:GT0792
Bio-0676
BRN 5387583
BSPBio_002285
C38H72N2O12
CCRIS 1961
CHEBI:2955
CHEMBL529
CID447043
CP62,993
CP-62993
CPD000471864
DCH3
Dihydrate, azithromycin
DivK1c_000233
DRG-0104
Funk brand OF azithromycin dihydrate
Goxal
Hemomycin
HMS1922G12
|
HMS2094M11
HMS500L15
HSDB 7205
IDI1_000233
KBio1_000233
KBio2_000787
KBio2_003355
KBio2_005923
KBio3_001505
KBioGR_000731
KBioSS_000787
Lesvi brand OF azithromycin dihydrate
LS-1834
Mack brand OF azithromycin dihydrate
Misultina
MLS001055353
MLS001066331
MLS001201763
MLS001304005
MLS001332499
MLS001332500
MolPort-002-507-426
Monohydrate, azithromycin
NCGC00090753-01
NCGC00090753-02
NINDS_000233
NSC643732
Pfizer brand OF azithromycin
Pfizer brand OF azithromycin dihydrate
Pharmacia brand OF azithromycin dihydrate
SAM002589961
SMR000471864
SPBio_001544
Spectrum_000307
SPECTRUM1503679
Spectrum2_001582
Spectrum3_000653
Spectrum4_000186
Spectrum5_001867
Sumamed
Toraseptol
Tromix
Ultreon
UNII-JTE4MNN1MD
Vinzam
Vita brand OF azithromycin dihydrate
XZ-450
Zentavion
ZIT
Zithromac
Zithromax
Zithromax IV
Zithromycin
Zitromax
Zitromax Avium 600
Zmas
Zmax
Z-Pak
|
|
16 |
|
Lopinavir |
Approved |
Phase 2 |
|
192725-17-0 |
92727 |
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
378, ABT
A 157378
A 157378.0
A-157378.0
A-157378-0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
ABT-378a-157378-0a-157378.0
AC1L3OPJ
AIDS032937
Aluviran
|
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Kaletra
Koletra
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
LPV
LS-173766
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
|
|
17 |
|
Enoxaparin |
Approved |
Phase 2 |
|
9005-49-6 |
772 |
Synonyms:
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
AC1L19ZN
AR-1E4539
CID772
Clexane
D006495
D017984
DB00407
DB01225
EMT 966
EMT 967
EMT966
EMT-966
EMT967
EMT-967
|
enoxaparin
Enoxaparine
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
LMWH
Lovenox
Lovenox HP
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
PK 10,169
PK10,169
PK-10,169
PK10169
PK-10169
|
|
18 |
|
Ritonavir |
Approved, Investigational |
Phase 2 |
|
155213-67-5 |
392622 |
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
538, ABT
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
A-84538
Abbott 84538
ABBOTT-84538
ABT 538
ABT 84538
ABT538
ABT-538
AC1L94GB
AC-733
AKOS000280930
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
DB00503
|
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
NSC693184
RIT
ritonavir
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
RTV
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
|
|
19 |
|
Tocopherol |
Approved, Investigational |
Phase 2 |
|
1406-66-2, 54-28-4 |
14986 |
Synonyms:
3,4-dihydro-2,7,8-Trimethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol
7,8-Dimethyltocol
7,8-dimethyltocolo-Xylotocopherol
Abortosan
adisseo Brand OF tocopherol
Alcala brand OF tocopherol acetate
Aliud brand OF tocopherol
Antioxidans e-hevert
Aquasol e
Arkopharma brand OF tocopherol acetate
AstraZeneca brand OF tocopherol acetate
Atarost brand OF tocopherol acetate
Ausrichter brand OF tocopherol
Auxina e
Balkanpharma brand OF tocopherol
Bayer brand OF tocopherol acetate
bio e
Biocur brand OF tocopherol acetate
biopto-e
Biosan
Bioweyxin
Blackmores brand OF tocopherol
Bottger brand OF tocopherol acetate
Cambridge laboratories brand OF tocopherol actetate
Dal e
Dal vita brand OF vitamin e succinate
Dal-e
Dal-vita brand OF vitamin e succinate
Davitamon
Dermorelle
Detulin
D-gamma-Tocopherol
DL-alpha-Tocopherol
DL-a-Tocopherol
DL-α-tocopherol
Dragees, vitamin-e
e Ferol
e Mulsin
e Vicotrat
e Vitamin e
Ecoro
e-Ferol
Elex verla
Embial
e-Mulsin
Ephynal
Eplonat
Equivit e
Eu rho brand OF tocopherol
EUNOVA vitamin e
Eusovit
e-Vicotrat
EVI-mirale, vitamin-e
Evion
e-Vitamin-ratiopharm
GNR Pharma brand OF tocopherol actetate
GNR-Pharma brand OF tocopherol actetate
Grace brand OF tocopherol
Grunwalder brand OF tocopherol
g-Tocopherol
Hervert brand OF tocopherol acetate
Heyl brand OF tocopherol acetate
Hydrovit e
ICN brand OF tocopherol acetate
Infirmarius rovit brand OF tocopherol
Infirmarius-rovit brand OF tocopherol
Internation animal health brand OF tocopherol acetate
Jenapharm brand OF tocopherol
Kentucky brand OF tocopherol
Kohler brand OF tocopherol
Lasar
Malton e
medphano Brand OF tocopherol acetate
Merck brand OF tocopherol acetate
Methyltocols
Micorvit e
MIP brand OF tocopherol acetate
Mowivit vitamin e
Mucos brand OF tocopherol acetate
Organon brand OF tocopherol acetate
O-Xylotocopherol
puncto e
Ratiopharm brand OF tocopherol
Richelet brand OF tocopherol acetate
|
Richtavit e
Riemser brand OF tocopherol
Roche nicholas brand OF tocopherol acetate
Rodisma med brand OF tocopherol
Rodisma-med brand OF tocopherol
Sanavitan S
Sanum kehlbeck brand OF tocopherol actetate
Sanum-kehlbeck brand OF tocopherol actetate
Schwarzhaupt brand OF tocopherol acetate
Sciencex brand OF tocopherol acetate
Scot tussin brand OF tocopherol acetate
Scot-tussin brand OF tocopherol acetate
Snow-e muscle, energy and feritility
Spondyvit
Stadapharm brand OF tocopherol
Steigerwald brand OF tocopherol acetate
Strathmann brand OF tocopherol
tocoferol
tocoferoles
Tocolion
Tocopa
Tocopharm
Tocopherol
tocophérol
Tocopherol ausrichter brand
Tocopherol balkanpharma brand
Tocopherol bayer
Tocopherol grace brand
Tocopherol grunwalder brand
Tocopherol infirmarius-rovit brand
Tocopherol kentucky brand
Tocopherol ratiopharm brand
Tocopherol rodisma-med brand
Tocopherol stadapharm brand
Tocopherol togal brand
Tocopherol twardy brand
Tocopherol verla brand
Tocopherol wiedemann brand
Tocopherol worwag brand
Tocopherols
Tocovital
Togal brand OF tocopherol
Togasan vitamin e
Troyapharm brand OF tocopherol acetate
Twardy brand OF tocopherol
Unique e
uno Vit
uno-Vit
UnoVit
Verla brand OF tocopherol
Veyx brand OF tocopherol
Vibolex
Vit e hydrosol
Vit. e stada
Vita e
Vita plus e
Vita-e
VitaE
Vitagutt vitamin e
Vitamin e al
Vitamin e dragees
Vitamin e evi mirale
Vitamin e gamma
Vitamin e MP
Vitamin e natur
Vitamin e sanum
Vitamin e suspension
Vitamin e, mowivit
Vitamin e, togasan
Vitamin e, vitagutt
Vitamin emp
Vitamin e-MP
Vitamin-e dragees
Vitamine e GNR
Vitamin-e evi-mirale
Vita-plus e
VitaPlus e
Vitazell
Wiedemann brand OF tocopherol
Wiedemann brand OF vitamin e succinate
Woelm brand OF tocopherol acetate
Worwag brand OF tocopherol
γ-tocopherol
|
|
20 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 2 |
|
21645-51-2 |
|
Synonyms:
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
|
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
|
|
21 |
|
Aluminum sulfate |
Approved |
Phase 2 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
22 |
|
Vitamin E |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-02-9 |
14985 |
Synonyms:
(+)-alpha-Tocopherol
(+)-a-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-dihydro-2,5,7,8-Tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'r,8'r)-alpha-Tocopherol
(2R,4'r,8'r)-a-Tocopherol
(2R,4'r,8'r)-α-tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-trimethyltocol
5,7,8-Trimethyltocol
a-D-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
alpha-Tocopherol
Amino-Opti-E
Aquasol E
a-Tocopherol
D-alpha-Tocopherol
|
Daltose
D-a-Tocopherol
delta-alpha-Tocopherol
Denamone
d-α-tocopherol
D-α-tocopherol
E-200 I.U. Softgels
E-Complex-600
E-Ferol
Eprolin
E-Vitamin succinate
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-Tocopherol
RRR-alpha-Tocopheryl
Tocopherol
Vitamin e
Vitamin ea
Vitamin Plus E Softgells
Vitec
α-tocopherol
|
|
23 |
|
Tocotrienol |
Investigational |
Phase 2 |
|
6829-55-6 |
|
24 |
|
N-(2-aminoethyl)-5-isoquinolinesulfonamide |
|
Phase 2 |
|
|
|
25 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
26 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
27 |
|
Anticoagulants |
|
Phase 2 |
|
|
|
28 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
29 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
30 |
|
Tocopherols |
|
Phase 2 |
|
|
|
31 |
|
Tocotrienols |
|
Phase 2 |
|
|
|
32 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
33 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
34 |
|
Antacids |
|
Phase 2 |
|
|
|
35 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
36 |
|
Antibodies |
|
Phase 1, Phase 2 |
|
|
|
37 |
|
Rho(D) Immune Globulin |
|
Phase 2 |
|
|
|
38 |
|
Vaccines |
|
Phase 1, Phase 2 |
|
|
|
39 |
|
Immunoglobulins, Intravenous |
|
Phase 2 |
|
|
|
40 |
|
gamma-Globulins |
|
Phase 2 |
|
|
|
41 |
|
Immunoglobulins |
|
Phase 1, Phase 2 |
|
|
|
42 |
|
Immunologic Factors |
|
Phase 1, Phase 2 |
|
|
|
43 |
|
interferons |
|
Phase 1, Phase 2 |
|
|
|
44 |
|
Poly I-C |
|
Phase 1, Phase 2 |
|
|
|
45 |
|
poly(I).poly(c12,U) |
|
Phase 1, Phase 2 |
|
|
|
46 |
|
Imiquimod |
Approved, Investigational |
Phase 1 |
|
99011-02-6 |
57469 |
Synonyms:
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-amino-1-Isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC1L1N2I
AC1Q4YO9
AC-529
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
Beselna
BIDD:GT0859
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
|
I06-0624
I06-2289
I0747
I5159_SIGMA
imiquimod
Imiquimod
IMIQUIMOD
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MolPort-002-507-845
MTD-39
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S1211_Selleck
S-26308
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
Zartra
ZINC19632912
Zyclara
|
|
47 |
|
Peramivir |
Approved, Investigational |
Phase 1 |
|
229614-55-5, 330600-85-6 |
151164 |
Synonyms:
(1S,2S,3S,4R)-3-(1-acetamido-2-ethylbutyl)-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
(1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
1A5BB290
229614-55-5
229614-56-6
3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid
3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID
330600-85-6
AC1L45SI
AC1L4BWX
BCX 1812
BCX1812
BCX-1812
BCZ
CHEBI:292932
|
CHEBI:41095
CHEMBL139367
CHEMBL332608
CID151164
CID154234
PeramiFlu
Peramivir
Peramivir anhydrous
Rapiacta
RWJ 270201
RWJ270201
RWJ-270201
S-021812
UNII-QW7Y7ZR15U
|
|
48 |
|
Inulin |
Approved, Investigational, Nutraceutical |
Phase 1 |
|
9005-80-5 |
24763 |
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
EINECS 232-684-3
|
INULIN
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
Inulin USP 27
LS-186416
LS-187349
|
|
49 |
|
Chlorine dioxide |
Investigational |
|
|
10049-04-4 |
|
50 |
|
Anti-Infective Agents |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 178)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response |
Completed |
NCT03701061 |
Phase 4 |
|
2 |
Oseltamivir (Tamiflu) Dosing Strategies for Use During Influenza Prophylaxis (VA01) |
Completed |
NCT00304434 |
Phase 4 |
Oseltamivir;Probenecid |
3 |
A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age |
Completed |
NCT02839330 |
Phase 3 |
|
4 |
A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions |
Completed |
NCT02107807 |
Phase 3 |
|
5 |
A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC |
Completed |
NCT02612909 |
Phase 2, Phase 3 |
|
6 |
A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects |
Completed |
NCT00434733 |
Phase 3 |
|
7 |
Safety and Immunogenicity of Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age |
Completed |
NCT01310413 |
Phase 3 |
|
8 |
A Blinded, Randomized Phase 2/3 Study to Assess Immunogenicity and Safety of Two Different Dose Levels of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Healthy Japanese Adult Population Aged 18 to 59 Years |
Completed |
NCT01382329 |
Phase 2, Phase 3 |
|
9 |
Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure |
Completed |
NCT01788228 |
Phase 3 |
|
10 |
Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers |
Completed |
NCT01987011 |
Phase 3 |
|
11 |
Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions. |
Completed |
NCT02091908 |
Phase 3 |
|
12 |
Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49 |
Completed |
NCT00539981 |
Phase 3 |
|
13 |
Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years. |
Completed |
NCT00328107 |
Phase 2, Phase 3 |
|
14 |
Efficacy of Oseltamivir in Reducing the Duration of Clinical Illness, Viral Shedding, and Transmissibility Reduction Within Households Among Participants in an Influenza Disease Burden Surveillance Cohort in Urban Dhaka, Bangladesh |
Completed |
NCT00707941 |
Phase 3 |
Oseltamivir;Placebo |
15 |
Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection: A Randomized, Open Label Clinical Trial |
Not yet recruiting |
NCT04391101 |
Phase 3 |
Convalescent plasma |
16 |
SEA022 Oseltamivir Treatment in Children Under One Year of Age With Moderate or Severe Influenza Lower Respiratory Tract Infection - a Clinical and Pharmacokinetic Study. |
Withdrawn |
NCT01546935 |
Phase 2, Phase 3 |
Oseltamivir |
17 |
A Single Center, Open-label, Phase I/II Study of Two 90 Microgram Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses |
Unknown status |
NCT00417560 |
Phase 1, Phase 2 |
|
18 |
Immunogenicity And Safety Of An Alum-Adjuvanted Inactivated H7N9 Influenza Vaccine |
Unknown status |
NCT03369808 |
Phase 1, Phase 2 |
|
19 |
A Phase II, Single Center, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With MF59-adjuvanted or Non-adjuvanted H5N3 Influenza Vaccines |
Completed |
NCT00478816 |
Phase 2 |
|
20 |
A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of an H5N1 Influenza Vaccine in Subjects Aged 6 Months to 17 Years |
Completed |
NCT00537524 |
Phase 2 |
|
21 |
A Trial to Evaluate the Immunogenicity of Accelerated Primary Vaccination With Monovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen in Association With AS03 Adjuvant in Adults Aged 18-64 |
Completed |
NCT00695669 |
Phase 2 |
|
22 |
Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study |
Completed |
NCT02229357 |
Phase 2 |
|
23 |
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010) |
Completed |
NCT01910519 |
Phase 2 |
|
24 |
High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial |
Completed |
NCT00298233 |
Phase 2 |
Oseltamivir |
25 |
A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of an H5N1-vaccine and a Seasonal Influenza Vaccine in Adult Subjects |
Completed |
NCT00481065 |
Phase 2 |
|
26 |
Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine |
Completed |
NCT01578317 |
Phase 1, Phase 2 |
|
27 |
A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects |
Completed |
NCT02436928 |
Phase 1, Phase 2 |
|
28 |
A Phase II Randomized Study of the Safety and Immunogenicity of Vaccination Strategies Using One or Two Clades and Different Schedules of H5N1 Unadjuvanted, Inactivated Subvirion Influenza Vaccines in H5 Naïve Healthy Adults |
Completed |
NCT00703053 |
Phase 2 |
|
29 |
A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects |
Completed |
NCT00561184 |
Phase 2 |
|
30 |
A Multicenter, Open-Label Study to Assess the Immunogenicity and Safety of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Healthy Young Adults Primed With a Two-Vaccination of a Recombinant H5N1 Influenza HA Vaccine |
Completed |
NCT01195038 |
Phase 2 |
|
31 |
A Multicenter, Non-Blinded, Dose Escalation Study to Evaluate the Immunogenicity, Safety and Optimal Dose of Three Doses Regimen of Recombinant Influenza H5N1 Vaccine, After Two Vaccinations Given 3 Weeks Apart, in Healthy Young Adults. |
Completed |
NCT00980447 |
Phase 2 |
|
32 |
A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1â„¢ |
Completed |
NCT02078674 |
Phase 1, Phase 2 |
|
33 |
Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities |
Completed |
NCT00311649 |
Phase 1, Phase 2 |
|
34 |
A Randomized, Double-Blinded, Phase I/II Study of the Safety, Reactogenicity, and Immunogenicity of an Inactivated Influenza Vaccine Derived From A/H5N1/Indonesia/05/05 (Clade 2) in Healthy Adults and Elderly Who Participated in a Previous A/H5N1/Vietnam/1203/2004 (Clade 1) Vaccine Study |
Completed |
NCT00680069 |
Phase 1, Phase 2 |
|
35 |
A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses |
Completed |
NCT02921997 |
Phase 2 |
AS03 |
36 |
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant |
Completed |
NCT03312231 |
Phase 2 |
AS03 |
37 |
A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages |
Completed |
NCT02213354 |
Phase 2 |
MF59 |
38 |
A Phase II Study in Healthy Adults 18-64 Years Old to Assess the Safety, Reactogenicity and Immunogenicity of a Seqirus A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without MF59(R) Adjuvant |
Completed |
NCT03682120 |
Phase 2 |
MF59 adjuvant |
39 |
A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine |
Completed |
NCT03318315 |
Phase 2 |
AS03 |
40 |
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects. |
Completed |
NCT01766921 |
Phase 2 |
|
41 |
Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years |
Completed |
NCT01416571 |
Phase 2 |
|
42 |
A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects. |
Completed |
NCT01776554 |
Phase 2 |
|
43 |
A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects. |
Completed |
NCT01776541 |
Phase 2 |
|
44 |
Phase II Study of a Pandemic Influenza Vaccine in Elderly Participants |
Completed |
NCT00376402 |
Phase 2 |
|
45 |
Phase II Study of a Pandemic Influenza Vaccine in Children |
Completed |
NCT00370864 |
Phase 2 |
|
46 |
A Phase 1/2, Randomized, Open-Label, Study to Assess the Immunogenicity and Safety of a Vaccine Enhancement Patch (VEP) When Administered With Two Doses of Intramuscular Inactivated Influenza H5N1 Vaccine in Healthy Adults |
Completed |
NCT01353534 |
Phase 1, Phase 2 |
Vaccine Enhancement Patch |
47 |
A Phase 1/2 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Infants, Children and Adolescents Aged 6 Months to 17 Years |
Completed |
NCT01052402 |
Phase 1, Phase 2 |
|
48 |
Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children |
Completed |
NCT00884182 |
Phase 2 |
|
49 |
A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 μg of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects |
Completed |
NCT00914771 |
Phase 2 |
|
50 |
An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years |
Completed |
NCT00895544 |
Phase 1, Phase 2 |
|
|